The infusion of a source of endothelial progenitors (EPCs) to limb ischemia (LB) patients has been used to increase angiogenesis. Because the formation of new blood vessels involves, in addition to EPCs, other cells and angiogenic regulators, we postulate that a combination cell therapy including EPCs and mesenchymal stem cells (a source of pericytes progenitors and angiogenic regulators) may represent a preferential stimuli for the development of blood vessels. In this phase I clinical trial, patients with LI were infused with a cell product consisting of autologous bone marrow-derived mononuclear and mesenchymal stem cells. After 10 2 months of follow-up, efficacy assessment demonstrated improvements in walking time, ankle brachial pressure, and quality of life. Concomitantly, angiographic and 99mTc-TF perfusion scintigraphy scores confirmed increased perfusion in the treated limbs. These results show that the use of a combination cell therapy is safe, feasible, and appears effective in patients with LI.
Sottiurai V. , White JVExtensive revascularization or primary amputation: which patients with critical limb ischemia should not be revascularized? Semin Vasc Surg. 2007;20(1):68-72.
2.
Aronow WSPeripheral arterial disease in the elderly. Clin Interv Aging . 2007;2(4):645-654.
3.
Kolvenbach R. , Kreissig C., Ludwig E., Cagiannos C.Stem cell use in critical limb ischemia. J Cardiovasc Surg. 2007;48(1):39-44.
4.
Tateishi-Yuyama E., Matsubara H., Murohara T., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360(9331):427-435.
5.
Miyamoto M., Yasutake M., Takano H., et al. Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant. 2004;13(4):429-437.
6.
Nizankowski R. , Petriczek T., Skotnicki A., Szczeklik A.The treatment of advanced chronic lower limb ischaemia with marrow stem cell autotransplantation. Kardio Pol. 2005;63(4):351-360.
7.
Lenk K., Adams V., Lurz P., et al. Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia . Eur Heart J. 2005; 26(18):1903-1909.
Gaengel K., Genove G., Armulik A., Betsholtz C.Endothelial-mural cell signaling in vascular development and angiogenesis . Arterioscler Thromb Vasc Biol.2009;29(5):630-638.
10.
Jin S.-W, Patterson C.The opening act: vasculogenesis and the origins of circulation. Arterioscler Thromb Vasc Biol.2009;29(5):623-629.
11.
Banfi A., von Degenfeld G., Blau HMCritical role of microenvironmental factors in angiogenesis. Curr Atheroscler Rep. 2005; 7(3):227-234.
12.
Chichester CO, Fernandez M, Minguell JJExtracellular matrix gene expression by human bone marrow stroma and by marrow fibroblasts. Cell Adhes Commun. 1993;1(2):93-99.
13.
Pittenger MF , Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284(5411):143-147.
Covas DT, Panepucci RA, Fontes AM, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol. 2008; 36(5):642-654.
16.
Crisan M., Deasy B., Gavina M., et al. Purification and long-term culture of multipotent progenitor cells affiliated with the walls of human blood vessels: myoendothelial cells and pericytes. Methods Cell Biol. 2008;86(1):295-309.
17.
Conget P., Minguell JJPhenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol. 1999;181(1):67-73.
18.
Minguell JJ , Fierro FA, Epunan MJ, Erices AA, Sierralta WDNonstimulated human uncommitted mesenchymal stem cells express cell markers of mesenchymal and neural lineages. Stem Cells Dev. 2005;14(4):408-414.
19.
Horwitz EM, Le Blanc K., Dominici M., et al, the International Society for Cellular Therapy.Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy . 2005;7(5):393-395.
20.
Morgan MB, Crayford T., Murrin B., Fraser SCDeveloping the Vascular Quality of Life Questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia. J Vasc Surg. 2001;33(4):679-687.
21.
Burgess EM, Matsen FA, Wyss CR, Simmons CWSegmental transcutaneous measurements of PO2 in patients requiring below-the-knee amputation for peripheral vascular insufficiency. J Bone Joint Surg Am. 1982;64(3):378-382.
22.
Milkiewicz M., Ispanovic E., Doyle JL, Haas TLRegulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol . 2006;38(3):333-357.
